PRAME expression in hairy cell leukemia

Arons, Evgeny; Suntum, Tara; Margulies, Inger; Yuan, Constance; Stetler‐Stevenson, Maryalice; Kreitman, Robert J.

doi:10.1016/j.leukres.2007.12.010

Cited by 5 publications

(5 citation statements)

References 38 publications

(55 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PRAME expression has been described in a variety of hematologic malignancies, including both acute and chronic myeloid and lymphocytic leukemias, hairy cell leukemia, Hodgkin’s lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, and multiple myeloma. PRAME overexpression in these tumors generally portends a poor prognosis with shorter overall survival and progression-free survival and lower chemotherapeutic response [ 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 ]. Some studies have described a favorable prognosis with PRAME overexpression in both acute myeloid and lymphoblastic leukemia in pediatric patients as well as acute myeloid leukemia in adults [ 39 , 40 , 41 , 42 ].…”

Section: Discussionmentioning

confidence: 99%

“…The CTA family comprises a number of genes whose expression is typically restricted to only male germ cells. These antigens are abnormally re-expressed in a variety of solid and hematologic malignancies [ 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 ]. PRAME overexpression is believed to prevent cell cycle arrest and apoptosis by inhibiting the retinoic acid signaling pathway.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Lack of PRAME Expression in Cutaneous T-Cell Lymphomas

et al. 2021

View full text Add to dashboard Cite

Cutaneous T-cell lymphomas (CTCLs) are rare tumors with no established markers that can reliably distinguish between benign and malignant lesions. Preferentially Expressed Antigen in Melanoma (PRAME) is a cancer/testis antigen that is found in many solid and hematologic malignancies. PRAME overexpression typically portends a poor prognosis and lower chemotherapeutic response. To date, no studies have established a role for PRAME in CTCL. An analysis was performed on 47 cases definitively diagnosed as CTCL: 25 cases of mycosis fungoides, 2 of Sezary syndrome, 5 of CD30+ lymphoproliferative disorder, 7 of primary cutaneous anaplastic large T-cell lymphoma, 3 of primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder, 1 of subcutaneous panniculitis-like T-cell lymphoma, and 4 of angiocentric T-cell lymphoma. PRAME immunohistochemistry was completely negative in all cases. PRAME expression was not found in any CTCL subtypes, suggesting that the pathogenesis of CTCL is not mediated by PRAME. Further study is required to identify biomarkers that might aid in the diagnosis and prognostication of CTCLs.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Lack of PRAME Expression in Cutaneous T-Cell Lymphomas

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Cutaneous melanoma [7] Non-melanoma skin cancer [8] Merkel cell carcinoma [8] Leukaemia; Acute Myeloid Leukaemia [4] Breast cancer [2] Ovarian cancer [2] Neuroblastoma [5] Non-small-cell lung cancer [6] 2. Molecular Background PRAME is a nuclear receptor, a transcriptional regulator, and a member of the cancer testis antigen (CTA) family of proteins.…”

Section: Referencementioning

confidence: 99%

“…The expression of PRAME is not universal among all cancers, but shows a broad pattern of upregulation in many of them [16][17][18]. For instance, high levels of PRAME expression have been documented in cutaneous melanoma, which is where the antigen was first discovered [8,19], but it has since been found to be expressed in various malignancies, including leukaemia [7], neuroblastoma [20], non-small-cell lung cancer [21], breast cancer [22], ovarian cancer [23], and various sarcomas [24,25]. PRAME has not been as widely researched in non-melanoma skin cancers (NMSCs) (Table 2).…”

Section: Prame and Cancermentioning

confidence: 99%

PRAME Updated: Diagnostic, Prognostic, and Therapeutic Role in Skin Cancer

Cassalia,

Danese,

Tudurachi

et al. 2024

IJMS

View full text Add to dashboard Cite

Preferentially Expressed Antigen in Melanoma (PRAME), a member of the cancer/testis antigen family, is central to the field of skin cancer diagnostics and therapeutics. As a nuclear receptor and transcriptional regulator, PRAME plays a critical role in inhibiting retinoic acid signalling, which is essential for cell differentiation and proliferation. Its aberrant overexpression in various malignancies, particularly cutaneous melanoma, is associated with more aggressive tumour phenotypes, positioning PRAME as both a diagnostic and prognostic marker. In melanoma, PRAME is typically highly expressed, in contrast to its weak or absent expression in benign nevi, thereby improving the accuracy of differential diagnoses. The diagnostic value of PRAME extends to various lesions. It is significantly expressed in uveal melanoma, correlating to an increased risk of metastasis. In acral melanomas, especially those with histopathological ambiguity, PRAME helps to improve diagnostic accuracy. However, its expression in spitzoid and ungual melanocytic lesions is inconsistent and requires a comprehensive approach for an accurate assessment. In soft tissue sarcomas, PRAME may be particularly helpful in differentiating melanoma from clear cell sarcoma, an important distinction due to their similar histological appearance but different treatment approaches and prognosis, or in detecting dedifferentiated and undifferentiated melanomas. In non-melanoma skin cancers such as basal cell carcinoma, squamous cell carcinoma, and Merkel cell carcinoma, the variable expression of PRAME can lead to diagnostic complexity. Despite these challenges, the potential of PRAME as a therapeutic target in melanoma is significant. Emerging immunotherapies, including T-cell-based therapies and vaccines targeting PRAME, are being investigated to exploit its cancer-specific expression. Ongoing research into the molecular role and mechanism of action of PRAME in skin cancer continues to open new avenues in both diagnostics and therapeutics, with the potential to transform the management of melanoma and related skin cancers.

show abstract

“…This is noticeable with both the preferentially expressed antigen of melanoma (PRAME) and Wilm's tumour-1 (WT-1). Both are expressed in a broad range of haematological malignancies including acute and chronic leukaemias, with PRAME being found in hairy cell leukaemia, myeloma and lymphomas, while WT-1 is demonstrated in MDS [64][65][66][67][68][69][70][71]. Data collected for PRAME highlight its ability to induce differentiation arrest in affected cells, as exemplified by its interaction with retinoic acid receptor to inhibit its action [72,73].…”

Section: The Leukaemia-associated Antigensmentioning

confidence: 99%

Tumour-associated antigens: considerations for their use in tumour immunotherapy

2011

View full text Add to dashboard Cite

Since their discovery, tumour-associated antigens (TAA) have provided highly inviting targets for cancer therapy, especially immunotherapy. Evidence now points to their involvement in the malignant phenotype of transformed cells and heightens their importance for being targeted by different treatments. TAA vary in their nature and pattern of expression and this influences the way therapy is directed towards them. While large numbers of these antigens have been isolated from solid tumours, fewer are linked with haematological malignancies. Those TAA found in this latter group of cancers, referred to as leukaemia-associated antigens (LAA), also appear to have significant potential for promoting the malignant phenotype and have been described in detail in terms of expression and therapy. Interestingly, the action of some of LAA in blood cancers, which are stem cell derived, could act as model for solid tumours, which are increasingly thought to be also derived from a cancer stem cell origin. In this review, TAA and their use in immunotherapy will be discussed. The nature and expression of these antigens will be described together with the events that provide tumours, including haematological cancers, with the ability to avoid immune deletion.

show abstract

PRAME expression in hairy cell leukemia

Cited by 5 publications

References 38 publications

Lack of PRAME Expression in Cutaneous T-Cell Lymphomas

Lack of PRAME Expression in Cutaneous T-Cell Lymphomas

PRAME Updated: Diagnostic, Prognostic, and Therapeutic Role in Skin Cancer

Tumour-associated antigens: considerations for their use in tumour immunotherapy

Contact Info

Product

Resources

About